CERE — Cerevel Therapeutics Holdings Balance Sheet
0.000.00%
- $8.19bn
- $7.68bn
- 36
- 15
- 91
- 44
Annual balance sheet for Cerevel Therapeutics Holdings, fiscal year end - December 31st, millions except per share.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | |
| Standards: | — | USG | USG | USG | USG |
| Status: | fx Preliminary | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | — | 384 | 566 | 892 | 991 |
| Net Total Receivables | — | — | — | 2.05 | 5.29 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | — | 391 | 578 | 906 | 1,007 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | — | 48.6 | 51.7 | 49.3 | 45.8 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | — | 445 | 689 | 1,018 | 1,243 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | — | 29.5 | 42.5 | 72.6 | 92.2 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | — | 60.8 | 110 | 497 | 570 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | — | 385 | 579 | 521 | 674 |
| Total Liabilities & Shareholders' Equity | — | 445 | 689 | 1,018 | 1,243 |
| Total Common Shares Outstanding |